GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects

G. Opiteck (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), E. Butz (Seattle, United States of America), S. Sugden (Montreal, Canada), R. Aranda (San Diego, United States of America), H. Ortega (San Diego, United States of America)

Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session: Clinical and laboratory pharmacology in asthma
Session type: E-poster session
Number: 1421
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Opiteck (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), E. Butz (Seattle, United States of America), S. Sugden (Montreal, Canada), R. Aranda (San Diego, United States of America), H. Ortega (San Diego, United States of America). GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects. 1421

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan
Source: Annual Congress 2010 - Airway smooth muscle cells
Year: 2010

Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

Selective versus non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005

Serotonin (5-hydroxytryptamine) modulates cytokine and chemokine production in lipopolysaccharide-primed human monocytes via stimulation of different 5-HT receptor subtypes
Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma
Year: 2005


A common intragenic marker of cysteinyl leukotrienes receptor-1 (T927C) does not correlate with a clinical response to the receptor's antagonist but is associated with peripheral blood eosinophilia
Source: Eur Respir J 2001; 18: Suppl. 33, 260s
Year: 2001

Distinct effects of the endothelin receptor antagonists PD 142893 (ET-A/B), BQ 788 (ET-B) and N-Ac-Trp-ET 1 Frg. 16-21 (ET-A) on oxidative stress-induced pulmonary hypertension in isolated rabbit lungs
Source: Eur Respir J 2001; 18: Suppl. 33, 198s
Year: 2001

Down-regulation of allergic reactions by stimulation of prostaglandin E receptor EP3 subtype
Source: Annual Congress 2004 - Insights into asthma and COPD
Year: 2004


Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events
Source: Eur Respir J 2015; 45: 1108-1118
Year: 2015



The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells
Source: Eur Respir J 2003; 22: Suppl. 45, 100s
Year: 2003

Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma.
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Year: 2019

Cystenyl-leukotriene receptor antagonist (LRA) inhibits respiratory burst of human neutrophils
Source: Eur Respir J 2003; 22: Suppl. 45, 316s
Year: 2003

In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist
Source: Eur Respir J 2007; 30: Suppl. 51, 25s
Year: 2007

The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model
Source: Eur Respir J 2001; 18: Suppl. 33, 406s
Year: 2001

The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation
Source: Eur Respir J 2005; 26: Suppl. 49, 733s
Year: 2005

An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019


The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood
Source: Eur Respir J 2004; 24: Suppl. 48, 218s
Year: 2004

Liver-X-receptor agonists, but not dexamethasone, inhibit leukotriene production from human white blood cells pretreated with GM-CSF and activated with fMLP
Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence
Year: 2007


Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects
Source: Eur Respir J 2008; 31: 311-319
Year: 2008



Effects of oral SCH 527123, a CXCR2 antagonist, on acquired immunity in healthy adults
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007


Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s)
Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Year: 2018